UL Acquires AWS Truepower to expand global renewable energy portfolio Blog Post

UL (Underwriters Laboratories), a global safety science leader, announces the acquisition of  AWS Truepower, a leading energy engineering services and advisory firm. This achievement expands UL’s global renewable energy portfolio by strengthening full lifecycle solutions for wind and solar energy sectors. AWS Truepower operates in Europe and Latin America through AWS Truepower SLU, a spanish company located at the Barcelona Scientific Park (PCB).

 

Half of patients with type 2 diabetes do not have their disease under control Blog Post

Therapeutic compliance in type 2 diabetes mellitus (DM2) is crucial. However, only 30%-50% of patients receiving oral antidiabetics, and not even 25% of those receiving insulin adhere to their treatment regimen1. The worst compliers are younger patients who, moreover, are at greater risk of developing cardiovascular complications. This was the claim of the specialists who attended Diabento, a symposium organized by Esteve, of more than 450 physicians from all around Spain who analyzed current and future challenges in DM2 from a multidisciplinary perspective. Esteve and PCB have been working closely since 2003.

 

IRB Barcelona and IBMB-CSIC have been presented with funding from AECC for cancer research Blog Post

Jelena Urosevic and Carles Barceló, postdoctoral fellows at the Institute for Research in Biomedicine (IRB Barcelona), and Elisa Martí Gorostiza, researcher at the Institut de Biologia Molecular de Barcelona (IBMB-CSIC) –both located at the Barcelona Science Park–  have officially been presented with funding over 5 years from the Asociación Española Contra el Cáncer (AECC) for their respective research projects on cancer.

 

The 16th edition of ‘Recerca en Societat’ program starts up at PCB Blog Post

Today, on 19 September 2016, the Barcelona Science Park (PCB) opens the enrollment period to participate in the experimental workshops ‘Fes recerca!’ (Do Research!) and ‘Descobreix la recerca!’ (Discover Research!), which gives the start to the 16th edition of ‘Recerca in Societat’ (Research in Society). This proposal of PCB to bring science to the public and encourage vocations among young people includes over 120  activities, involving annually about 6,000 people.

 

IRB Barcelona presents the “Alumni of Excellence Award” to David Vilchez Blog Post

Today the Institute for Research in Biomedicine (IRB Barcelonahas presented David Vilchez, group leader at the CECAD-Cluster of Excellence in Cologne, Germany, with a commemorative certificate naming him as the first winner of the Alumni of Excellence Award. Vilchez obtained his PhD from IRB Barcelona in 2008, and three years ago he began his own group in Germany, where he has been awarded an ERC Starting Grant.

 

Ferrer, IBEC and Mind the Byte join forces to study new molecules against cancer metastasis Blog Post

The pharmaceutical company Ferrer has created a consortium with the Institute for Bioengineering of Catalonia (IBEC) and the bioinformatics company Mind the Byte, located at the Barcelona Science Park (PCB), to study the development of new therapeutic molecules against cancer metastasis. The work will follow the research on cadherin interaction and its role in cells that cause metastasis conducted by Dr. Xavier Trepat, ICREA professor at IBEC and one of the few scientists to have won three grants from the European Research Council (ERC).  

 

Cells move en masse towards rigid tissues Blog Post

In a study published today in the journal Science, researchers at IBEC, based at PCB, have shown that several types of cells are attracted to the most rigid areas of tissues. The discovery contradicts the traditional view that cell movement is guided primarily by variations in the chemical concentration of proteins and ions. The new phenomenon, collective durotaxis, opens new avenues to control tumor growth and improve wound healing.

 

Sights set on the next generation of shuttle peptides to target the brain Blog Post

IRB Barcelona scientists Benjamí Oller, Macarena Sánchez, Ernest Giralt, and Meritxell Teixidó, all from the Peptides and Proteins Lab of the Chemistry and Molecular Pharmacology Programme, have written a review on the emerging field of shuttle peptides—molecules that have the capacity to transport drugs across the blood-brain barrier and thus treat diseases affecting the central nervous system. The article will be featured on the cover of September’s issue of Chemical Society Reviews.

 

Researchers at IRB Barcelona discover the hidden potential of disordered proteins Blog Post

Prostate cancer, Alzheimer’s, Parkinson’s…these three diseases are associated with proteins that share a common feature, namely disordered regions that have no apparent rigid three-dimensional structure. In spite of the potential of these regions as therapeutic targets, it was believed that drugs could not be directed to them. But now scientists at the Institute for Research in Biomedicine (IRB Barcelona), based at the Barcelona Science Park (PCB), have rediscovered their utility as drug targets.